BioMarin Program For Morquio A Syndrome Treatment

Armen Hareyan's picture
Advertisement

BioMarin Pharmaceutical announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio A Syndrome. BioMarin plans to initiate a Phase 1/2 clinical trial in the first quarter of 2009.

Advertisement

"With two MPS drugs on the market, we plan to leverage our clinical, manufacturing and regulatory expertise to efficiently develop a treatment for Morquio patients," said Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin. "Our planned program includes a clinical assessment study to measure the depth and breadth of disease as well as a separate GALNS Phase 1/2 study in Morquio Type A patients. Preliminary studies are promising and indicate that our drug candidate binds naturally to bone matrix and can adequately reach the growth cartilage after IV infusion. The skeletal system disease is a primary concern in the treatment of this disease."

The company has successfully developed and manufactures two FDA-approved enzyme replacement therapies for the treatment of MPS I and MPS VI. Naglazyme (galsulfase) MPS VI is wholly developed and commercialized by BioMarin. Aldurazyme (laronidase) for MPS I is manufactured by BioMarin and marketed by Genzyme Corporation.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement